Knee osteoarthritis lacks effective solutions; current treatments mainly provide temporary symptom relief, while many patients endure years of limited quality of life before eventually progressing to joint replacement. Cell-Lipo addresses this gap by enabling physicians to provide a standardized, autologous regenerative-cell treatment at the point of care. It matters because millions of patients need a safe, practical option that can improve outcomes and potentially delay or avoid major surgery.

Cell-Lipo harnesses the regenerative potential of adipose-derived cells to treat osteoarthritis, supported by robust scientific and clinical data. Our simple, automated point-of-care device makes this treatment accessible to millions of patients, creating the potential for a new standard of care in osteoarthritis.

Knee osteoarthritis lacks effective solutions; current treatments mainly provide temporary symptom relief, while many patients endure years of limited quality of life before eventually progressing to joint replacement. Cell-Lipo addresses this gap by enabling physicians to provide a standardized, autologous regenerative-cell treatment at the point of care. It matters because millions of patients need a safe, practical option that can improve outcomes and potentially delay or avoid major surgery.

Cell-Lipo harnesses the regenerative potential of adipose-derived cells to treat osteoarthritis, supported by robust scientific and clinical data. Our simple, automated point-of-care device makes this treatment accessible to millions of patients, creating the potential for a new standard of care in osteoarthritis.

"The Mayo Clinic–ASU MedTech Accelerator gave us invaluable access to world-class clinicians, mentors, and industry experts. Their feedback helped sharpen our clinical and commercial strategy and accelerate Cell-Lipo’s path toward bringing a new standard of care to patients."

Ofer Barshem
Co-founder and CEO, Cell-Lipo